Loading
Alpha-emitting PSMA therapy produced its cleanest first-in-human data yet, and PSMA PET continued to reshape staging and treatment selection.
In 50 patients with PSMA-PET-positive mCRPC after an AR pathway inhibitor, dose escalation of Bayer's albumin-binding actinium-225 PSMA agent produced no dose-limiting toxicities or treatment-related deaths. At the 125 kBq/kg level, 83% of patients had a PSA decline of at least 50% and 67% at least 90%, with a 71% measurable soft-tissue response rate.
SourcePresentations reinforced PSMA PET positivity as the selection tool for lutetium and actinium PSMA therapies, and its role in detecting recurrence at low PSA.
Source